Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

STADA Arzneimittel AG M&A Activity 2017

Jul 4, 2017

412_rns_2017-07-04_7e2e8aa4-7928-4f85-9ac4-6dfaa844e089.html

M&A Activity

Open in viewer

Opens in your device viewer

News Details

Ad-hoc | 4 July 2017 00:23

STADA Arzneimittel AG confirms that Bain Capital and Cinven are considering to apply for an exemption from one-year exclusion period for the submission of a renewed voluntary public takeover offer

STADA Arzneimittel AG / Key word(s): Miscellaneous

04-Jul-2017 / 00:23 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.


Bad Vilbel, July 3, 2017 – STADA Arzneimittel AG confirms that Nidda Healthcare Holding AG, the acquiring company of Bain Capital and Cinven, gave notice to be considering to submit an application to the German Federal Financial Supervisory Authority (BaFin) for an exemption from the one-year exclusion period to make a renewed voluntary public takeover offer under section 26(2) of the German Securities Acquisition and Takeover Act (WpÜG). STADA is currently assessing whether the company would give its consent to the exemption from the exclusion period and will keep both the capital market and the public updated on further progress in this regard, in line with the applicable legal requirements.

Contact:

STADA Arzneimittel AG / Investor Relations / Leslie Iltgen / Stadastraße 2-18 / 61118 Bad Vilbel – Germany /

Tel.: +49 (0) 6101 603-173 / Fax: +49 (0) 6101 603-215 / E-mail: [email protected]

Or visit us on the internet at www.stada.com


04-Jul-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.dgap.de


Language: English
Company: STADA Arzneimittel AG
Stadastraße 2-18
61118 Bad Vilbel
Germany
Phone: +49 (0)6101 603- 113
Fax: +49 (0)6101 603- 506
E-mail: [email protected]
Internet: www.stada.de
ISIN: DE0007251803, DE0007251845,
WKN: 725180, 725184,
Indices: MDAX
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
End of Announcement DGAP News Service

show this